Titrating for antiproteinuric effect: The clue to renoprotection?

Journal of Human Hypertension

Volumn 10, Issue 10, 1996, Pages 669-673

  Navis, G ^a   De Zeeuw, D ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

ACE inhibitors; Chronic renal failure; Prevention; Proteinuria

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDOMETACIN;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE SEVERITY; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; PROTEIN RESTRICTION; PROTEINURIA; SODIUM INTAKE;

HUMANS; KIDNEY FAILURE, CHRONIC; PROTEINURIA;

EID: 0030480828     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (47)

1. Mitch WE, Buffington G, Lemaan J, Walser M. Progression of renal failure: a simple method of estimation. Lancet 1976; ii: 1326-1331.
2. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med 1988; 318: 1657-1666.
3. Brenner BM, Meyer TW, Hostetter TW. Dietary protein and the progressive nature of kidney disease: role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis of aging, renal ablation and intrinsic renal disease. N Engl J Med 1982; 307: 652-659.
4. Alvestrand A, Gutierrez A, Bucht H, Bergström J. Reduction of blood pressure retards the progression of chronic renal failure in man. Nephrol Dial Transplant 1988; 3: 624-631.
5. Maschio G et al. Effect of the angiotensin converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939-945.
6. Levey AS et al for the MDRD study group. Effects of dietary protein restriction on the progression of advanced renal disease in the modification of diet in renal disease study. Am J Kidney Dis 1996; 27: 652-663.
7. Pedrini MT et al. The effect of dietary protein restriction on the progression of diabetic and non-diabetic renal diseases: a meta-analysis. Ann Int Med 1996; 124: 627-632.
8. Klahr S et al. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877-884.
9. Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macro-molecules? (editorial). Kidney Int 1990; 38: 384-394.
10. Williams PS, Pass G, Bone JM. Renal pathology and proteinuria determine progression in untreated mild/moderate chronic renal failure. Quart J Med 1988; 67: 343-354.
11. Locatelli F et al. Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Nephrol Dial Transplant 1996; 11: 461-467.
12. Wight JP, Salzano S, Brown CB, El Nahas AM. Natural history of chronic renal failure: a reappraisal. Nephrol Dial Transplant 1992; 7: 379-383.
13. Brazy PC, Fitzwilliam JF. Progressive renal disease: role of race and antihypertensive medications. Kidney Int 1990; 37: 1113-1119.
14. Ahlem J. Incidence of human chronic renal insufficiency. A study of the incidence and pattern of renal insufficiency in adults during 1966-71 in Gothenburg. Acta Med Scand 1975; 198 (Suppl 582): 1-50.
15. Stenvinkel P, Alvestrand A, Bergström J. Factors influencing progression in patients with chronic renal failure. J Int Med 1989; 226: 183-188.
16. Rutherford WE et al. Chronic progressive renal disease: rate of change of serum creatinine concentration. Kidney Int 1977; 11: 62-70.
17. Hannedouche T et al. Effect of moderate protein restriction on the rate of progression of renal failure. Kidney Int 1989; 36 (Suppl 27): S91-S95.
18. Rosman JB et al. Protein-restricted diets in chronic renal failure: a four-year follow-up shows limited indications, Kidney Int 1989; 36 (Supp 27): S96-S102.
19. Isles CG, McLay A, Boulton-Jones JM. Recovery in malignant hypertension presenting as acute renal failure. Q J Med 1984; 212: 439-452.
20. Hauser AC, Derfler K, Balcke P. Progression of renal insufficiency in analgesic nephropathy: impact of drug abuse. J Clin Epidemiol 1991; 44: 53-56.
21. Beukhof JR et al. Toward individual prognosis of IgA nephropathy. Kidney Int 1986; 29: 549-556.
22. Mogensen CE. Natural history and potential prevention of diabetic nephropathy in insulin-dependent and non-insulin-dependent diabetic patients. In: El Nahas AM, Mallick NP, Anderson S (eds). Prevention of progressive chronic renal failure. Oxford University Press: Oxford, 1993, pp 259-302.
23. Donadio JV et al. Idiopathic membranous glomerulopathy. Kidney Int 1988; 33: 708-715.
24. Hunt LP, Short CD, Mallick NP. Prognostic indicators in patients presenting with the nephrotic syndrome. Kidney Int 1988; 34: 382-388.
25. Kincaid-Smith P, Becker G. Reflux nephropathy and chronic atrophis pyelonephritis: a review. J Infect Dis 1978; 138: 174-180.
26. El Khatib MT, Becker GJ, Kincaid-Smith PS. Morphometric aspects of reflux nephropathy. Kidney Int 1987; 32: 261-266.
27. Morita M, White RHR, Coad NAG, Raafat T. The glomerular changes in children with reflux nephropathy. J Pathol 1990; 162: 245-253.
28. Lewis EJ, Gunsicker LG, Baim RP, Rohde RD for the collaborative study group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
29. Kamper AL, Strandgaard S, Leyssac PP. Effect of enalapril on progression of chronic renal failure. Am J Hypertens 1992; 5: 423-430.
30. Björck S et al. Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. Br Med J 1990; 300: 904-907.
31. El Nahas AM et al. Selective effect of low protein diets in chronic renal diseases. Br Med J 1987; 289: 1337-1341.
32. Praga M et al. Long term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 1982; 20: 240-248.
33. Gansevoort RT, de Zeeuw D, de Jong PE. Long-term benefits of the antiproteinuric effect of ACE-inhibition in non-diabetic renal disease. Am J Kidney Dis 1993; 2: 202-206.
34. Apperloo AJ, de Zeeuw D, de Jong PE. Short-term antiproteinuric response to antihypertensive therapy predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 1994; 45 (Suppl 45): S174-S178.
35. Rossing P, Hommel E, Smidt UM, Parving H-H. Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int 1994; 45 (Supp 45): S145-S149.
36. Idelson BA, Smithlime N, Smith GW, Harrington JT. Prognosis in steroid treated idiopathic nephrotic syndrome. Ann Int Med 1988; 137: 891-896.
37. Williams PS, Bone JM. Immunosuppression can arrest progressive renal failure due to idiopathic membranous glomerulonephritis. Nephrol Dial Transplant 1988; 4: 181-188.
38. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993-2000.
39. Wapstra FH et al. Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis. Clin Sci 1996; 90: 393-401.
40. Apperloo AJ, de Zeeuw D, de Jong PE. The initial GFR decline on antihypertensive treatment in long term intervention studies is reversible after withdrawal of treatment. JASN 1994; 5: 324(A).
41. Navis GJ et al. Moderate sodium restriction in hypertensive subjects: renal effects of ACE inhibition. Kidney Int 1987; 31: 815-819.
42. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of lisinopril. Kidney Int 1989; 36: 272-279.
43. Jerums G, Allen TJ, Tsalamandris C, Cooper ME. Angiotensin converting enzyme inhibition and calcium channel blockade in incipient diabetic nephropathy. Kidney Int 1992; 41: 904-911.
44. Gansevoort RT, de Zeeuw D, de Jong PE. Additive antiproteinuric effect of ACE inhibition and a low protein diet in human renal disease. Nephrol Dial Transplant 1995; 10: 497-504.
45. Gansevoort RT et al. Effects of the angiotensin II receptor antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994; 12 (Suppl 2): S37-S42.
46. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45: 861-867.
47. Buter H et al. Hydrochlorothiazide potentiates the antiproteinuric efficacy of ACE inhibition in patients with non-diabetic renal disease. Kidney Int abstract (in press).